01 6Fasenra
02 5Of which, Benralizumab royalty
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 949
2019 Revenue in Millions : 704
Growth (%) : 35
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 20
2019 Revenue in Millions : 84
Growth (%) : -76
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,258
2020 Revenue in Millions : 949
Growth (%) : 33
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 142
2020 Revenue in Millions : 104
Growth (%) : 53
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 163
2021 Revenue in Millions : 142
Growth (%) : 15
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 1,396
2021 Revenue in Millions : 1,258
Growth (%) : 11
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 1,553
2022 Revenue in Millions : 1,396
Growth (%) : 11
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 185
2022 Revenue in Millions : 163
Growth (%) : 27
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 297
2017 Revenue in Millions : 1
Growth (%) : 29600%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 704
2018 Revenue in Millions : 297
Growth (%) : 137
LOOKING FOR A SUPPLIER?
